ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-EGFR/Anti-c-Met Bispecific Antibody-drug Conjugate VBC101

Its studies are led by VelaVigo Cayman.

Furthest: phase 2, since Aug 15, 20251 company-led study, 1 open or runningNext primary completion: Jul 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
VelaVigo Cayman11 open or runningphase 2since Aug 15, 2025Aug 15, 2025Jul 1, 2027phase 2 · NCT07136779

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 15, 2025First study: phase 2 study in Participants With Advanced Solid Tumor MalignanciesFirst studyNCT07136779 · 310 planned · United States

Ahead

  1. Jul 1, 2027Primary completion: phase 2 study in Participants With Advanced Solid Tumor MalignanciesNCT07136779

TargetBeta

EGFR →MET →read by rule
“A nanobody-based antibody-drug conjugate (ADC) composed of a low-affinity antibody fragment targeting epidermal growth factor receptor (EGFR) coupled with a high-affinity antibody fragment targeting hepatocyte growth factor receptor (HGFR; c-Met) ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
amivantamabruleJohnson & Johnsonphase 316
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
HS-20117Hansoh Pharmaceutical Groupphase 33
pamvatamigruleBetta Pharmaceuticalsphase 25
TQB2922Sino Biopharmaceuticalphase 25
TQB6411Sino Biopharmaceuticalphase 23
Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412ruletavotek-biotherapeuticsphase 12
HS-20122Hansoh Pharmaceutical Groupphase 12
Anti-EGFR/c-Met/c-Met-Topoisomerase-1 Inhibitor Trispecific Antibody-drug Conjugate BG-C0902ruleBeOne Medicinesphase 11
Anti-EGFR/c-Met-CPT-113 Antibody-drug Conjugate JNJ-95437446Johnson & Johnsonphase 11
HLX48Fosun Pharmaphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07136779Participants With Advanced Solid Tumor Malignancies · United States2RecruitingJul 1, 2027310

How it is read

Names in the registry

  • “VBC101”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.